echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Clinical approval of recombinant human anti TNF α monoclonal antibody for injection

    Clinical approval of recombinant human anti TNF α monoclonal antibody for injection

    • Last Update: 2020-04-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Jiankangyuan and Lizhu group's joint-venture subsidiary announced today (March 7) that Zhuhai Lizhu monoclonal antibody Biotechnology Co., Ltd

    (hereinafter referred to as monoclonal antibody company) applied for clinical research of recombinant human anti-tumor necrosis factor alpha monoclonal antibody for injection (hereinafter referred to as TNF - α) approved by the State Food and Drug Administration (SFDA)

    On March 4, 2014, McAb company received the approval document for clinical trials of drugs issued by SFDA, with the approval number of 2014l00371, and approved the McAb company to declare the anti-tumor necrosis factor monoclonal antibody for phase I clinical trials

    Zhuhai Lizhu McAb Biotechnology Co., Ltd

    is jointly invested and established by jiankangyuan and Lizhu group, with a registered capital of 300 million yuan

    Lizhu group holds 51% of its equity and jiankangyuan, the controlling shareholder of Lizhu, holds 49% of its equity

    Lizhu McAb was founded in 2010, introducing a professional team to carry out strategic development of McAb products, At present, jiankangyuan, as the controlling shareholder of Lizhu group, directly and indirectly holds 73.16% equity of McAb company

    According to reports, TNF - α is a class 1 biological product independently developed by the company to achieve strategic transformation, which is mainly used in rheumatoid arthritis, psoriasis, ankylosing spondylitis and other autoimmune diseases

    In 2013, the sales amount of similar foreign products was close to 30 billion US dollars: TNF - α similar products include anacept of Amgen, adamumumab of Abbott, infliximab of Johnson & Johnson and gelimumumab

    According to incomplete statistics, the sales amount in 2013 reached 8.3 billion US dollars, 10.7 billion US dollars, 8.9 billion US dollars and 930 million US dollars respectively; follow-up arrangement: after obtaining the clinical approval, the company will quickly organize phase I clinical trials, Increase the control of the original research drug, and explore the key indicators of product safety, efficacy and initial dose

      After obtaining the above approval documents, McAb company will organize and implement the clinical trial as soon as possible in accordance with the requirements of SFDA clinical trial, including adding the original research drug as the control drug in the PD study, initially exploring the efficacy of the product, further refining and improving the program with the clinical research responsible unit before the implementation of the clinical trial, and paying close attention to the same products and animal tests during the clinical trial The potential safety risk of exposure, combined with the non clinical and clinical of similar products, and the non clinical research of this product, is designed as the initial measurement of safety

    After the clinical approval of TNF - α monoclonal antibody is obtained, it is expected that there will be clinical approval for tumor products in the future.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.